Arlington, MA, United States of America

Eden Fucci


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Eden Fucci

Introduction

Eden Fucci is an accomplished inventor based in Arlington, MA (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of therapeutics aimed at addressing aldehyde toxicity. His innovative work has the potential to impact various medical conditions where aldehyde toxicity plays a critical role.

Latest Patents

Eden Fucci holds 1 patent for his invention titled "Polymorphic compounds and uses thereof." This patent provides freebase and salt forms, along with compositions and methods useful for treating various conditions linked to aldehyde toxicity. The invention focuses on the administration of small molecule therapeutics that act as scavengers for toxic aldehydes, offering a promising approach to mitigate their harmful effects.

Career Highlights

Eden Fucci is currently employed at Aldeyra Therapeutics, Inc., where he continues to advance his research and development efforts. His work at the company emphasizes the importance of innovative solutions in the treatment of diseases associated with toxic aldehydes. His dedication to improving patient outcomes through scientific discovery is evident in his ongoing projects.

Collaborations

Eden collaborates with talented professionals in his field, including Amanda Buist and Stephen Gitu Machatha. These partnerships enhance the research environment and foster the exchange of ideas, ultimately leading to more effective therapeutic solutions.

Conclusion

Eden Fucci's contributions to the field of medicinal chemistry exemplify the impact of innovation in healthcare. His patent on polymorphic compounds showcases his commitment to addressing critical medical challenges. Through his work at Aldeyra Therapeutics, Inc., he continues to pave the way for advancements in the treatment of conditions related to aldehyde toxicity.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…